Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder.

the impact of ADHD on workplace productivity and costs to employers has focused on the need to increase the diagnosis and treatment of ADHD in adults.13 The study, conducted by Kessler et al. at a large manufacturing firm and published in 2009, found that ADHD was associated with a 4% to 5% reduction in on-the-job productivity, the equivalent of losing 10 to 12 work days in a 250-day work year. The cost to employers for lost work performance was estimated to be $4,336 per employee with ADHD, which translates to $8,241 per 100 workers, assuming a conservative 1.9% prevalence of adult ADHD.13 These findings suggest that treatment of this disabling condition in adults may have a substantial economic benefit to employers as well as to the patients themselves. Furthermore, an analysis of pharmacy and medical claims data obtained from a large managed care plan revealed that annual total costs for adults with ADHD were $3,020 per person, slightly more than the total annual cost for adults with seasonal allergies and less than those incurred by adults with depression or diabetes.14